Harrow, Inc. Entity Listing, Par Value Per Share
Harrow, Inc. (HROW) reported Entity Listing, Par Value Per Share of $0.00 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Notes › Cover Page
dei:EntityListingParValuePerShare · last filed 2026-05-11
- Harrow, Inc. entity listing, par value per share for the quarter ending 2026-03-31 was $0.00, a 0.00% change year-over-year.
- Harrow, Inc. entity listing, par value per share for the quarter ending 2025-03-31 was $0.00.
| Period end | Entity Listing, Par Value Per Share 3 month | Entity Listing, Par Value Per Share 6 month | Entity Listing, Par Value Per Share 9 month |
|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |